Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models

Abstract Pseudomonas aeruginosa is a formidable pathogen that is responsible for a diverse spectrum of human infectious diseases, resulting in considerable annual mortality rates. Because of biofilm formation and its ability of rapidly acquires of resistance to many antibiotics, P. aeruginosa relate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feng Yang, Jiang Gu, Liuyang Yang, Chen Gao, Haiming Jing, Ying Wang, Hao Zeng, Quanming Zou, Fenglin Lv, Jinyong Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ca5d3ae9b83b4366abc7e80e971eb9cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca5d3ae9b83b4366abc7e80e971eb9cd
record_format	dspace
spelling	oai:doaj.org-article:ca5d3ae9b83b4366abc7e80e971eb9cd2021-12-02T12:32:01ZProtective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models10.1038/s41598-017-04029-52045-2322https://doaj.org/article/ca5d3ae9b83b4366abc7e80e971eb9cd2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04029-5https://doaj.org/toc/2045-2322Abstract Pseudomonas aeruginosa is a formidable pathogen that is responsible for a diverse spectrum of human infectious diseases, resulting in considerable annual mortality rates. Because of biofilm formation and its ability of rapidly acquires of resistance to many antibiotics, P. aeruginosa related infections are difficult to treat, and therefore, developing an effective vaccine is the most promising method for combating infection. In the present study, we designed a novel trivalent vaccine, PcrV28-294-OprI25-83-Hcp11-162 (POH), and evaluated its protective efficacy in murine pneumonia and burn models. POH existed as a dimer in solution, it induced better protection efficacy in P. aeruginosa lethal pneumonia and murine burn models than single components alone when formulated with Al(OH)3 adjuvant, and it showed broad immune protection against several clinical isolates of P. aeruginosa. Immunization with POH induced strong immune responses and resulted in reduced bacterial loads, decreased pathology, inflammatory cytokine expression and inflammatory cell infiltration. Furthermore, in vitro opsonophagocytic killing assay and passive immunization studies indicated that the protective efficacy mediated by POH vaccination was largely attributed to POH-specific antibodies. Taken together, these data provided evidence that POH is a potentially promising vaccine candidate for combating P. aeruginosa infection in pneumonia and burn infections.Feng YangJiang GuLiuyang YangChen GaoHaiming JingYing WangHao ZengQuanming ZouFenglin LvJinyong ZhangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Feng Yang Jiang Gu Liuyang Yang Chen Gao Haiming Jing Ying Wang Hao Zeng Quanming Zou Fenglin Lv Jinyong Zhang Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
description	Abstract Pseudomonas aeruginosa is a formidable pathogen that is responsible for a diverse spectrum of human infectious diseases, resulting in considerable annual mortality rates. Because of biofilm formation and its ability of rapidly acquires of resistance to many antibiotics, P. aeruginosa related infections are difficult to treat, and therefore, developing an effective vaccine is the most promising method for combating infection. In the present study, we designed a novel trivalent vaccine, PcrV28-294-OprI25-83-Hcp11-162 (POH), and evaluated its protective efficacy in murine pneumonia and burn models. POH existed as a dimer in solution, it induced better protection efficacy in P. aeruginosa lethal pneumonia and murine burn models than single components alone when formulated with Al(OH)3 adjuvant, and it showed broad immune protection against several clinical isolates of P. aeruginosa. Immunization with POH induced strong immune responses and resulted in reduced bacterial loads, decreased pathology, inflammatory cytokine expression and inflammatory cell infiltration. Furthermore, in vitro opsonophagocytic killing assay and passive immunization studies indicated that the protective efficacy mediated by POH vaccination was largely attributed to POH-specific antibodies. Taken together, these data provided evidence that POH is a potentially promising vaccine candidate for combating P. aeruginosa infection in pneumonia and burn infections.
format	article
author	Feng Yang Jiang Gu Liuyang Yang Chen Gao Haiming Jing Ying Wang Hao Zeng Quanming Zou Fenglin Lv Jinyong Zhang
author_facet	Feng Yang Jiang Gu Liuyang Yang Chen Gao Haiming Jing Ying Wang Hao Zeng Quanming Zou Fenglin Lv Jinyong Zhang
author_sort	Feng Yang
title	Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
title_short	Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
title_full	Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
title_fullStr	Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
title_full_unstemmed	Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
title_sort	protective efficacy of the trivalent pseudomonas aeruginosa vaccine candidate pcrv-opri-hcp1 in murine pneumonia and burn models
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/ca5d3ae9b83b4366abc7e80e971eb9cd
work_keys_str_mv	AT fengyang protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT jianggu protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT liuyangyang protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT chengao protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT haimingjing protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT yingwang protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT haozeng protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT quanmingzou protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT fenglinlv protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels AT jinyongzhang protectiveefficacyofthetrivalentpseudomonasaeruginosavaccinecandidatepcrvoprihcp1inmurinepneumoniaandburnmodels
_version_	1718394242527657984

Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models

Ejemplares similares